Simple Summary Immunotherapy has demonstrated the ability to reduce the risk of
recurrence for melanoma following surgical resection and improve survival in patients with …

Melanoma represents the most aggressive and the deadliest form of skin cancer. Current
therapeutic approaches include surgical resection, chemotherapy, photodynamic therapy …

Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM)
and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ …

Purpose Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1–derived
oncolytic immunotherapy designed to selectively replicate within tumors and produce …

A unique collaboration of multidisciplinary experts from the European Dermatology Forum,
the European Association of Dermato-Oncology and the European Organization for …

Simple Summary Melanoma is a major public health issue that claims the lives of thousands
of people every year. Furthermore, the outlook for the coming years is not encouraging with …

Cutaneous malignant melanoma (melanoma) is characterized by a high mutational load,
extensive intertumoral and intratumoral genetic heterogeneity, and complex tumor …

Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and
causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts …

Background In the BRIM-3 trial, vemurafenib was associated with risk reduction versus
dacarbazine of both death and progression in patients with advanced BRAF V600 mutation …

Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF
and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and …